Board and Management
Cypralis is built on the world class expertise and experience of senior leaders from the biopharma industry who are focussed on scientific and clinical innovation and excellence.
Hans Fliri Ph.D, Chairman/CEO
Hans Fliri has more than 35 years’ experience in the healthcare sector having held senior management positions in global pharmaceutical and biotechnology companies including research and management positions at Sandoz (now Novartis) in Basel between 1977 and 1994, was Senior Director of anti-infective drug discovery and lead generation at Rhone-Poulenc Rorer and later Aventis in Paris (1994-2000) and Vice President of Drug Discovery at Cetek Corporation (2001-2002) in the US. In 2005 he orchestrated a management buyout to create Selcia Ltd which he led to a successful exit in 2017. He holds a PhD in chemistry from the University of Innsbruck, did postdoctoral studies at the ETH Zurich and at MIT and is the author of approximately 60 scientific articles and patents.
Michael Peel Ph.D, CSO
Michael Peel has 30 years’ experience in the pharmaceutical industry and joined Cypralis from Scynexis Inc, where he was Director of Discovery. Whilst at Scynexis he was responsible for building their chemistry services group and directing DMPK and biology for in-house research. He led their in-house cyclophilin inhibitor programs, opening several avenues into new biology and new potential applications for cyclophilin inhibition in virology, ophthalmology and immunology. Prior to Scynexis, Mike worked for Glaxo Inc. in Research Triangle Park, North Carolina where he led several research projects in inflammation, cancer and virology, and played a key role in GSK’s kinase research programme. Mike holds a Ph.D in chemistry from Sheffield University and undertook his post-doctoral studies at Wayne State University (Detroit).
Andreas Rummelt Ph.D, Non-Executive Director
Andreas Rummelt has over 25 years of experience in the pharmaceutical industry, primarily with Novartis where he was a member of the Novartis Executive Committee from 2006 until 2010 with responsibility for drug development, technical operations, quality assurance and global manufacturing strategy. He was CEO of the generics division of Novartis (Sandoz) from 2004 until 2010. He is Managing Partner of InterPharmaLink AG, Basel, and is on the boards of Alexion Pharmaceuticals, Inc., Xellia Pharmaceuticals ApS and Habasit Holding AG/Habasit AG. Dr. Rummelt graduated with a Ph.D in Pharmaceutical Sciences from the University of Erlangen-Nürnberg, Germany in 1983 and received Executive Training in General Management and Leadership from IMD, INSEAD and Harvard Business School.
Nicola Baker-Munton CPA EPA, Non-Executive Director
Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem Intellectual Property Management Limited and has 30 years’ experience in the IP profession. Based on a joint honours degree in biology and biochemistry, Nicola qualified as a UK Patent Agent and European Patent Attorney at The Wellcome Foundation Limited and founded Stratagem IPM in 1999, which has subsequently become the leading specialist company providing active strategic management of intellectual property portfolios from inception through development to market.
Kim Haworth MSc FCCA, CFO
Kim Haworth has over 25 years of financial and management experience, and specialises in many areas including pharmaceutical, manufacturing and financial services. She was European Group Controller for GE Life and Pensions from 2004 to 2008 and was part of a team to sell the insurance divisions to Swiss Re and LV=. She transferred to LV= as Financial Controller of their Retirement Solutions Division and later was part of a team to sell LV Asset Management division to Threadneedle Asset Management. In 2012 she went on to join Friends Life Investments as Finance Director and as part of a team to build Friends Life inhouse Asset Manager. In 2016 she formed her own consultancy and acts as finance director to a portfolio of SME’s. She has a MSc in finance and is a qualified accountant with ACCA.
Please contact us to explore opportunities for collaboration or investment.